Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NouvNeu001 in Parkinson's Disease
NCT06167681Phase 2Recruiting
- Sponsor
- iRegene Therapeutics
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
A Phase 2 trial of NOUVNEU001 in Parkinson's disease (PD), sponsored by iRegene Therapeutics. Started Jan 2024; status: recruiting.
02
Drugs
NOUVNEU001
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06167681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06167681.